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Abstract 
Background: The I164L mutation on the dhfr gene confers high level resistance to sulfadoxine–pyrimethamine (SP) 
but it is rare in Africa except in a cluster of reports where prevalence >10% in highland areas of southwest Uganda 
and eastern Rwanda. The occurrence of the dhfr I164L mutation was investigated in community surveys in this area 
and examined the relationship to migration.
Methods: A cross-sectional prevalence survey was undertaken in among villages within the catchment areas of two 
health facilities in a highland site (Kabale) and a highland fringe site (Rukungiri) in 2007. Sociodemographic details, 
including recent migration, were collected for each person included in the study. A total of 206 Plasmodium falcipa-
rum positive subjects were detected by rapid diagnostic test; 203 in Rukungiri and 3 in Kabale. Bloodspot samples 
were taken and were screened for dhfr I164L.
Results: Sequence analysis confirmed the presence of the I164L mutations in twelve P. falciparum positive samples 
giving an estimated prevalence of 8.6% in Rukungiri. Of the three parasite positive samples in Kabale, none had 
I164L mutations. Among the twelve I164L positives three were male, ages ranged from 5 to 90 years of age. None of 
those with the I164L mutation had travelled in the 8 weeks prior to the survey, although three were from households 
from which at least one household member had travelled during that period. Haplotypes were determined in non-
mixed infections and showed the dhfr I164L mutation occurs in both as a N51I + S108N + I164L haplotype (n = 2) 
and N51I + C59R + S108N + I164L haplotype (n = 5). Genotyping of flanking microsatellite markers showed that 
the I164L occurred independently on the triple mutant (N51I, C59R + S108N) and double mutant (N51I + S108N) 
background.
Conclusions: There is sustained local transmission of parasites with the dhfr I164L mutation in Rukungiri and no 
evidence to indicate its occurrence is associated with recent travel to highly resistant neighbouring areas. The emer-
gence of a regional cluster of I164L in SW Uganda and Rwanda indicates that transmission of I164L is facilitated by 
strong drug pressure in low transmission areas potentially catalysed in those areas by travel and the importation of 
parasites from relatively higher transmission settings.
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Background
The antifolate sulfadoxine–pyrimethamine (SP) is widely 
used for intermittent preventive treatment of malaria in 
pregnant women (IPTp) and was recently recommended 
for intermittent preventive treatment in children and 
infants (IPTi) [1]. In addition, another antifolate, co-tri-
moxazole (trimethoprim–sulfamethoxazole), is recom-
mended by the World Health Organization (WHO) for 
treatment of childhood febrile diseases and for prophy-
laxis against opportunistic infections in HIV-infected 
patients in Africa. Commonly occurring mutations at 
codons 51, 59, 108 and 164 of the dhfr gene of malaria 
parasite Plasmodium falciparum are associated with 
resistance to SP, and cumulatively they confer increas-
ingly high levels of resistance. The triple mutant haplo-
type N51I, C59R and S108  N has been long established 
in Africa, but the combination of all 4 mutations remains 
rare despite the fact that it confers a higher level of resist-
ance and became established in Southeast Asia as early as 
1997 [2].
A review of published literature in 2012, identified 183 
surveys in 114 unique geographical localities in Africa, 
where P. falciparum isolates were tested for mutations 
at codon 164 of dhfr. Of 19,597 isolates tested, just 130 
(0.7%) were positive for I164L [3]. The mutation occurs 
at low level in multiple locations; 3% prevalence in west-
ern Kenya [4, 5]; 4% in Blantyre, Malawi [6]; 0.6% in the 
Central African Republic [7]; 1.1% in Comoros [8]; 1.0% 
in southern Madagascar [8] and 2% in Angola [9]. So far, 
it only occurs in significant numbers in Uganda [10, 11] 
and Rwanda.
Early surveys for the I164L mutant in Uganda in 
2002–2004, found just a single I164L mutation among 
480 isolates from six sites across Uganda [12]. The 
I164L mutant was 1 among 80 pre-treatment samples 
(mutation prevalence, 1.25%) from a clinic in Kanungu 
in southwest Uganda. By 2005, prevalence of I164L in 
southwest Uganda was increasing. Lynch et  al. looked 
at I164L among malaria patients attending health facili-
ties in highland and fringe highland areas of southwest 
Uganda in 2005 [13]. The I164L mutation was found at 
14% prevalence in Kabale (highland) and 4.2% prevalence 
in Rukungiri (fringe highland) [13]. In the same year 
malaria patients attending a clinic in Rukara in neigh-
bouring Rwanda were found to have 11.4% prevalence 
of I164L [14]. Rukara is just 120  km from Kabale and 
200 km from Rukungiri suggesting a common source of 
I164L. Patients in Mashesha, western Rwanda which is 
400 km from Kabale, Uganda were screened in the same 
study, and no I164L was present [14] (see Fig. 1) support-
ing the view that 164L had a restricted focal distribution. 
More recent surveys in clinics 2015 in Mubuga in western 
Rwanda (0% prevalence) and Ruhuha in Eastern Rwanda 
(10.2% prevalence) confirm that this is still the case [15] 
(see Fig. 2). This cluster of reports of elevated prevalence 
of I164L in clinical isolates from SW Uganda [13] and 
bordering Eastern Rwanda [14] supports the view that 
focal transmission of highly resistant malaria occurs in 
the region. However, in each of these studies the reported 
prevalence of I164L was among patients attending clinics 
with confirmed cases of symptomatic malaria and these 
may have been home treated with SP.
To know the extent of the mutation in the parasite 
reservoir in SW Uganda, cross sectional community 
surveys were carried out to detect and screen asympto-
matic infections for I164L and determine the baseline 
prevalence of this mutation. Surveys had previously been 
conducted in 2007 among communities in the catch-
ment area of the health facilities where malaria patients 
were originally screened in 2005 [13]. The prevalence of 
the I164L mutation was measured among asymptomatic 
infections, and looked at the number of dhfr resistance 
lineages from which these were derived. The travel his-
tories of parasite positive cases with I164L and without 
I164L mutation were recorded to examine the extent to 
which migration or travel outside the study areas may 
explain the occurrence of infections with I164L.
Methods
Study sites
A cross-sectional prevalence survey was undertaken in 
villages within the catchment areas of two health facili-
ties in Kabale and Rukungiri districts in 2007. Four vil-
lages in each district were randomly chosen and surveyed 
in their entirety. The primary sampling unit for the study 
was the household. All households in the selected village 
who had members present, and/or consented to the study 
were surveyed. Study sites are described elsewhere [16]. 
Kabale is a highland area (mean altitude 2200 m) where 
only three parasite positive samples were detected out of 
911 sampled at the time of the study. Rukungiri is a fringe 
highland (mean altitude 1500  m) area in Uganda where 
the mean parasite positivity rate based on cross-sectional 
community surveys for P. falciparum was 12.1% (95% CI 
10.0–14.2) at the time of the study [16].
Collection of travel data
A structured household questionnaire was used to 
capture information on household residents and visi-
tors’ sociodemographic, travel and malaria control and 
prevention in the household. Specific to mobility, par-
ticipants were asked details of their travel outside their 
sub-county of residence during the 8 weeks prior to the 
survey. As well as information on whether the partici-
pant travelled, they were also asked their dates of depar-
ture and return to estimate duration of exposure, their 
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Fig. 1 Percentage prevalence of I164L mutation detected in Uganda 2003–2015 shown (black and white circles) with place name, year of sampling, 
study reference, roads (white lines) and estimated transmission risk [28]
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Fig. 2 a–c Malaria rapid diagnostic test results,  MSP119 seroprevalence and I164L prevalence in Rukungiri district, Uganda
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destination sub-county and district, their reason for 
travel and whether they used an insecticide-treated net 
when travelling.
Sample collection and laboratory analysis
Bloodspots for samples were taken on  Whatman® 
3MM filter paper, dried and stored with silica gel. Out 
of 2125 samples collected in both sites, 206 subjects 
found  Paracheck® positive. Samples were analysed for 
the I164L mutation on dhfr using methods described in 
Lynch et  al. [13]. DNA was prepared from bloodspots 
using a Chelex extraction method and PCR amplification 
of dhfr carried out as previously described [17]. Ampli-
fied PCR products were screened for dhfr sequence vari-
ants at five loci where single nucleotide polymorphisms 
(SNPs) are known; dhfr codons 50, 51, 59, 108, 164. PCR 
products were spotted in a 12 by 8-grid and cross-linked 
onto nylon membranes and probed for sequence poly-
morphisms by hybridization to specific oligonucleotide 
probes as described previously [17]. Probed blots were 
visualized using ECF substrate and detection using a 
phosphoimager (GE Healthcare, Buckinghamshire, UK). 
Output was recorded through viewing of digitally cap-
tured images of chemifluorescent signal.
The presence, absence, and relative abundance of 
hybridization signal was recorded for every probe at each 
locus. A sample was considered to have a single haplo-
type when only one sequence variant was found at each 
locus. Blood samples were categorized as having a single, 
a majority or mixed form of sequence at every SNP locus. 
Majority and mixed genotype infections were differenti-
ated according to the relative intensity of signal.
Polymorphic microsatellite repeats were studied in the 
flanking region of dhfr on chromosome 4. Microsatellite 
markers located 0.3, 4.4 and 5.3 kb upstream from codon 
108 were analysed, amplifying each locus by PCR then 
measuring fragment size on an ABI 3730 sequencer and 
using the software Genemapper (Applied Biosystems, 
Warrington, Cheshire, UK). A semi-nested PCR design 
was used and the primer sequences and PCR reaction 
conditions are described elsewhere [18].
Ethics, consent and permissions
Ethical clearance was obtained from Ugandan National 
Council for Science and Technology (HS-35) and Lon-
don School of Hygiene & Tropical Medicine (3053). In 
addition, the blood sampling was demonstrated to Local 
Chairmen (LC) and executive committees of each village 
surveyed, and approval for the survey sought. Informed 
consent was obtained from the head of household for all 
human adult participants as well as any children under 
18. Parasite positive individuals were referred to the local 
health facility to receive free treatment.
Results
Prevalence of molecular markers for drug resistance 
at community level
Only three parasite positive samples were found in 
Kabale and none of these had the I164L mutation. The 
prevalence of point mutations in the Rukungiri samples 
is shown in Table 1.
Sequence analysis confirmed the presence of the I164L 
mutations in 12 of the 139 P. falciparum positive sam-
ples from Rukungiri from which DNA was successfully 
amplified, giving an estimated I164L prevalence of 8.6% 
(n = 12/139).
Haplotypes could be confidently determined in isolates 
which did not have mixed signal in any of the codons. The 
haplotype frequencies among this subset of samples are 
shown in Table 2. There was a predominance of the triple 
mutant haplotype IRNI (N51I, C59R  +  S108N) a small 
number of double mutant haplotypes (S108N  +  N51I), 
and zero sensitive/non-mutant haplotypes. Seven hap-
lotypes containing the I164L could be confidently deter-
mined. In two cases the I164L was on an ICNL haplotype 
(S108N +  N51I +  I164L) and in five cases on an IRNL 
(S108N + C59R + N51I + I164L).
Polymorphism at the three flanking microsatellite 
loci is shown in Table  3. Dhfr mutations from the 2007 
Table 1 Prevalence of wild-type and mutant codons in the 
dhfr genes of Plasmodium falciparum among subjects sam-
pled during cross-sectional community survey, 2007 [16]
Gene, codon Amino acid Prevalence (%) Rukungiri
Wild-type
 51 N 0/139 (0)
 59 C 5/139 (4)
 108 S 0/139 (0)
 164 I 131/139 (94)
Mutant
 51 I 139/139 (100)
 59 R 134/139 (96)
 108 N 139/139 (100)
 164 L 12/139 (8.6)
Table 2 Point mutation haplotype frequencies in  the dhfr 
genes [proportion (%) of positive subjects], 2007
Haplotype Rukungiri
NCSI 0/128 (0)
IRNI 120/128 (94.5)
ICNI 1/128 (1.6)
ICNL 2/128 (2.3)
IRNL 5/128 (1.6)
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community survey are shown with their associated 
microsatellite flanking haplotypes and they are com-
pared dhfr mutant alleles in clinical isolates from 2005 
(13). Allele sizes at the microsatellite loci show the triple 
mutant IRNI haplotype is associated with microsatellite 
0.3/4.4/5.3 kb flanking haplotype 108/176/203. This was 
true in both 2005 and 2007 and is confirmation that this 
mutant allele derives from the common triple mutant lin-
eage found throughout Africa. The IRNL haplotype was 
associated with the same microsatellite flanking haplo-
type 108/176/203 indicating that the I164L was addition-
ally acquired onto the triple mutant lineage. Interestingly 
the double mutant ICNI has several independent, local 
origins each different from the triple mutant.
In 2007, the ICNL mutant haplotype was found in asso-
ciation with microsatellite haplotype 87/172/205 while in 
2005 it was linked to haplotype 87/178/193. A number of 
microsatellite haplotypes are commonly associated with 
the ICNI double mutant in East Africa and the I164L 
mutation has clearly been acquired independently on at 
least two of these lineages.
Travel data was available for all 12 subjects with the 
I164L mutations; none had travelled in the 8 weeks prior 
to the survey. Two of the four villages surveyed were 
where most of the I164L mutations were found with 
five people from one village living within 600 m of each 
other (which was identified as a cluster for P. falciparum 
positive subjects). In the second village, three subjects 
lived within 550 m distance of each other while another 
I164L positive person lived approximately 1.8  km away 
(Fig. 2a–c). The two remaining villages surveyed each had 
one person with positive for I164L. Four of those sur-
veyed were from households in which there were other 
parasite positive individuals (Table 4). Nine were female, 
three were male and ages ranged from 5 to 90 year of age.
Discussion
The I164L mutation on the dhfr gene is known to con-
fer high level resistance to SP but it is rare in African P. 
falciparum except in southwest Uganda and bordering 
areas of eastern Rwanda. Previously all the I164L muta-
tion prevalence reports from this geographical area had 
been measured in patient isolates collected at health 
facilities. One possible explanation for the higher rate of 
I164L among symptomatic infections is that there was 
prior selection by home or community treatment before 
attendance at the clinic. In Uganda, at the time of the 
study, there was a policy of home treatment with chloro-
quine-SP (CQ + SP) branded as ‘Homapak’ which could 
have pre-selected resistance mutations prior to clinic 
attendance. Although home treatment via ‘homapak’ was 
not policy in Rwanda, CQ  +  SP was national first-line 
treatment between 2001 and 2005 and widely available 
through both public and private sector facilities [19].
In this current study, community surveys were carried 
out to identify the reservoir of P. falciparum infection and 
test these parasites for dhfr I164L. It was confirmed that 
the parasite reservoir around Rukungiri clinic the I164L 
mutation occurs at a prevalence rate of 8.6%. This is in 
fact higher than was recorded among patients attending 
Table 3 Microsatellite haplotypes associated with the dhfr 
mutant alleles found in 2005 and 2007
Fragment sizes are shown in base pairs and are standardised across the 2 years 
by running fragments on the same machine with identical size standard
a I164L mutations
Haplotype 0.3 kb 4.4 kb 5.3 kb 2005 2007
1 87 172 205 2 ICNLa
2 87 176 193 1 IRNI
3 87 176 203 1 ICNI
4 87 176 210 1 ICNI
5 87 178 193 1 ICNI, 1 ICNLa 1 ICNI
6 108 176 193 1 IRNI 2 IRNI
7 108 176 199 1 IRNI
8 108 176 201 1 IRNI
9 108 176 203 57 IRNI + 6 
IRNLa
49 IRNI + 4 
IRNLa
10 108 1 IRNLa
11 108 176 209 1 IRNI
12 108 176 4 IRNI
13 108 203 1 IRNI
14 110 176 201 1 IRNI
15 110 176 203 3 IRNI
16 110 176 1 IRNI
17 112 176 203 2 IRNI
Table 4 Demographic and  travel history for  twelve sub-
jects for  which an I164L Plasmodium falciparum mutant 
was recovered
Altitude Age Sex Travel < 
8 weeks
HH member 
travel last 
8 weeks
Total HH mem-
bers +ve out of 
those sampled
1551–1600 5 M N N 1/4
1551–1600 10 F N N 1/5
1500–1550 9 F N Y 3/7
1500–1550 10 F N Y 1/5
1450–1499 5 F N N 1/4
1450–1499 6 M N Y 1/3
1450–1499 13 F N N 1/7
1400–1450 5 F N N 4/4
1400–1450 10 F N N 1/1
1400–1450 29 F N N 3/7
1400–1450 90 F N N 2/5
1350–1399 7 M N N 1/7
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Rukungiri clinic in 2005 among whom the prevalence of 
I164L was 4.2%. Based on these findings, conclusions are 
that the I164L mutations in Rukungiri malaria infection 
reservoir has been sustained or has slightly increased 
over the 2 years between sampling in 2005 and 2007.
A higher prevalence of I164L was found among patients 
in Kabale in 2005, but the community survey of 2007 
managed to identify only 3 infections because transmis-
sion intensity is very low. There are previous reports of 
an association between malaria infection in Kabale resi-
dents with recent travel to higher transmission areas par-
ticularly to the region north of Kabale [20, 21] where the 
tea estates around Fort Portal in western Uganda draw 
a significant seasonal labour workforce (see Fig. 2). It is 
possible that the I164L mutation was imported to Kabale 
by seasonal migrants returning from that region. A prev-
alence of 36% dhfr I164L was recorded in 2013 among 
pregnant women (n  =  55) receiving SP-IPTp [11] This 
indicates that I164L is abundant in the parasite popula-
tion there, although clearly the prevalence estimates will 
be elevated among populations receiving SP prophylaxis.
Microsatellite analysis from 2007 samples in the study 
sites indicate similar results to the 2005 analysis (12) 
in that the I164L mutation has occurred on the triple 
mutant ‘IRNI’ (N51I  +  C59R  +  S108N) background as 
well as on at least 2 dhfr double mutant lineages ICNI 
(N51I + S108N). Strong drug pressure is the most likely 
explanation for the high occurrence of I164L, and its 
repeated de novo emergence in this area. A further pos-
sibility however is the emergence of adaptations in other 
genes in the same pathway, which can compensate for 
deleterious effect of the 164L mutation in these popula-
tions. Increased copy number of the GTP cyclohydro-
lase (gch1) gene is strongly associated with the dhfr 164L 
mutation in southeast Asia [22]. Duplications in the 
promotor of gch1 are found in East Africa and reported 
to be particularly common in Malawi [23] although not 
found in association with 164L. Further exploration of 
copy number variation in genes of the folate biosynthesis 
pathway in parasites of SW Uganda and Eastern Rwanda 
is warranted. Additional investigations are warranted, 
in particular examination of contemporary samples col-
lected from this particular geographical area.
In general, stronger drug selection is expected in areas 
of lower transmission because in less malaria-exposed 
populations a higher proportion of infections are symp-
tomatic and therefore more likely to be treated with 
anti-malarial drugs. Transmission intensity is very low 
in the Kabale highlands, but in the highland fringe areas 
of Fort Portal, Kanungu, Rukungiri, Rukara and Ruhuha 
transmission is considered to be meso- to hyper-endemic 
with localized variation across the region [24] (see Fig. 1). 
Local transmission occurs in these areas, this is reflected 
in the age distribution of infection and the incidence pro-
file of malaria disease in these communities.
The strength of selection for SP resistance will have 
changed since the first report of I164L in 2003. In Uganda 
the first-line recommended treatment was changed in 
2006 from SP + CQ to artemether +  lumefantrine [25], 
although use of SP continued throughout the transition 
to artemisinin-based combination therapy (ACT), and 
SP continues to be used in IPTp to the present day. In 
Rwanda, implementation of ACT as first-line treatment 
also started in 2006 during which a complete changeo-
ver was made from SP  +  CQ to ACT alone [26]. The 
prevalence of I164L mutations appears to be increasing 
nevertheless which suggests the selection of I164L is con-
tinuing and perhaps it may be promoted by the high inci-
dence of symptomatic infections in highland populations.
It is clear from this and other molecular surveillance 
studies carried out since 2003 that a highly SP resistant 
sub-population of P. falciparum exists and is maintained 
in the highland fringe areas extending from Rwenzori 
mountains in Uganda down into eastern Rwanda. The 
northern limits of its distribution are yet to be deter-
mined but it is absent in western Rwanda and this pattern 
of distribution suggests that a particular combination 
of factors such as selection and migration promote and 
maintain the I164L in this area. With increasing invest-
ment in road infrastructure throughout sub-Saharan 
Africa [27], and in the Great Lakes region in particular, 
the risk of spread of highly resistant mutations is higher 
than ever before. It will be important to monitor the 
spread of highly resistant I164L mutants in Uganda in 
particular. Previous work has shown that gene flow has 
played a central role in the establishment of resistance to 
CQ and SP at sites across Africa, so the spread of mutants 
has the potential of becoming a wider problem. Further 
analysis of parasites from the western Uganda, and from 
Eastern areas of DR Congo bordering both Rwanda and 
Uganda would determine the geographical extent of the 
I164L cluster.
Conclusions
Findings in 2005 and in this currently reported 2007 work 
demonstrate the prevalence of I164L in demographically 
different populations from those normally tested for 
I164L. In our 2005 study, patients presenting were men 
between 18 and 30  years who had travelled  <6  weeks 
previously, while in the community survey presented 
here those with I164L mutations were aged between 5 
and 90 years and were both male and female and had not 
travelled recently (Table 4). In further investigations aim-
ing to define the limits of the sub-region affected by the 
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highly SP resistant parasites it will be necessary to survey 
at population level, with particular attention to seasonal 
or circular migrants. Not just on the more commonly 
undertaken studies screening pregnant women on IPTp 
or children  <5  years recruited to anti-malarial efficacy 
studies.
The sustained presence of, and even increase in, I164L 
mutations in the sub-region even after the introduc-
tion of ACT, strongly indicates the need for a targeted 
approach to the control of malaria in pregnancy. Given 
the likely presence of I164L, screening and treating con-
firmed malaria cases in pregnancy would be more appro-
priate than SP-IPTp in the affected region.
The emergence of a regional cluster of I164L in SW 
Uganda and Rwanda indicates that transmission of 
I164L is facilitated by strong drug pressure in low trans-
mission areas and potentially catalyzed in some areas by 
travel between relatively higher to lower transmission 
settings. Attention to treatment policy on the fringes 
of malaria distribution is particularly important in the 
context of malaria elimination zones on the African 
continent.
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